HFS
ORMP icon

Hopwood Financial Services’s Oramed Pharmaceuticals ORMP Stock Holding History

Hopwood Financial Services’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200
Closed -$528 – 229
2025
Q3 		$528 Hold
200
– – ﹤0.01% 307
2025
Q2 		$450 Hold
200
– – ﹤0.01% 293
2025
Q1 		$428 Hold
200
– – ﹤0.01% 297
2024
Q4 		$484 Buy
+200
New +$475 ﹤0.01% 306

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
AF
Aquamarine Financial George Town $1.37B AUM
SCM
SB Capital Management Encino, California $273M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Hopwood Financial Services's ORMP Position: Q4 2025 in Review

Hopwood Financial Services sold out of Oramed Pharmaceuticals (ORMP) in Q4 2025, closing a stake of 200 shares — an estimated $528 sold.

Hopwood Financial Services first reported a position in ORMP in Q4 2024 and held it in 4 quarters. The position peaked at $528 in Q3 2025. 57 funds tracked by Wall St. Rank hold ORMP as of Q4 2025.

  • Hopwood Financial Services reported no remaining Oramed Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Hopwood Financial Services sold 200 Oramed Pharmaceuticals shares in Q4 2025, an estimated $528.
  • Hopwood Financial Services first reported a position in Oramed Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Hopwood Financial Services's Oramed Pharmaceuticals position peaked at $528 in Q3 2025.
  • 57 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2025.

Based on Hopwood Financial Services's 13F filing for Q4 2025, filed 16 Jan 2026.